- JP-listed companies
- Kidswell Bio Corporation
- Financials
- Provision for income taxes
Kidswell Bio Corporation (4584)
Market cap
¥12B
P/E ratio
KidsWell Bio develops biosimilar drugs and regenerative medicine treatments using SQ-SHED stem cells from baby teeth for pharmaceutical partners and rare disease patients.
| Period End | Provision for income taxes (Million JPY) | YoY (%) |
|---|---|---|
| Mar 31, 2025 | 94 | +5961.12% |
| Mar 31, 2024 | 2 | +28.18% |
| Mar 31, 2023 | 1 | -19.33% |
| Mar 31, 2022 | 2 | -15.78% |
| Mar 31, 2021 | 2 | -16.78% |
| Mar 31, 2020 | 2 | +12.63% |
| Mar 31, 2019 | 2 | +0.00% |
| Mar 31, 2018 | 2 | -21.49% |
| Mar 31, 2017 | 2 | +27.37% |
| Mar 31, 2016 | 2 | +0.00% |
| Mar 31, 2015 | 2 |